Pieris Pharmaceuticals Crecimiento futuro
Future controles de criterios 0/6
Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Pieris Pharmaceuticals.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 28.4% |
Tasa de crecimiento de los ingresos | n/a |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | None |
Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%
Jul 11Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Pieris Pharmaceuticals no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.
Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.
Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
9/30/2024 | 1 | -16 | -28 | -28 | N/A |
6/30/2024 | 21 | -24 | -38 | -38 | N/A |
3/31/2024 | 41 | -16 | -50 | -50 | N/A |
12/31/2023 | 43 | -25 | -54 | -54 | N/A |
9/30/2023 | 47 | -28 | -47 | -47 | N/A |
6/30/2023 | 33 | -27 | -46 | -46 | N/A |
3/31/2023 | 17 | -41 | -49 | -48 | N/A |
12/31/2022 | 26 | -33 | -61 | -60 | N/A |
9/30/2022 | 28 | -35 | -59 | -58 | N/A |
6/30/2022 | 27 | -42 | -65 | -64 | N/A |
3/31/2022 | 27 | -47 | -19 | -18 | N/A |
12/31/2021 | 31 | -46 | -9 | -8 | N/A |
9/30/2021 | 25 | -51 | -11 | -10 | N/A |
6/30/2021 | 24 | -48 | -3 | -3 | N/A |
3/31/2021 | 32 | -38 | -44 | -43 | N/A |
12/31/2020 | 29 | -37 | -49 | -46 | N/A |
9/30/2020 | 45 | -26 | -50 | -46 | N/A |
6/30/2020 | 57 | -15 | -56 | -52 | N/A |
3/31/2020 | 51 | -22 | -57 | -52 | N/A |
12/31/2019 | 46 | -28 | -55 | -52 | N/A |
9/30/2019 | 34 | -36 | -49 | -48 | N/A |
6/30/2019 | 27 | -40 | -51 | -49 | N/A |
3/31/2019 | 33 | -28 | -49 | -48 | N/A |
12/31/2018 | 29 | -27 | -3 | -1 | N/A |
9/30/2018 | 42 | -8 | 1 | 3 | N/A |
6/30/2018 | 38 | -8 | N/A | 53 | N/A |
3/31/2018 | 28 | -18 | N/A | 55 | N/A |
12/31/2017 | 25 | -18 | N/A | 50 | N/A |
9/30/2017 | 10 | -32 | N/A | 48 | N/A |
6/30/2017 | 7 | -31 | N/A | 9 | N/A |
3/31/2017 | 6 | -27 | N/A | 9 | N/A |
12/31/2016 | 6 | -23 | N/A | -14 | N/A |
9/30/2016 | 5 | -19 | N/A | -10 | N/A |
6/30/2016 | 5 | -17 | N/A | -10 | N/A |
3/31/2016 | 4 | -15 | N/A | -7 | N/A |
12/31/2015 | 3 | -14 | N/A | -13 | N/A |
9/30/2015 | 4 | -15 | N/A | -10 | N/A |
6/30/2015 | 4 | -13 | N/A | -8 | N/A |
3/31/2015 | 4 | -13 | N/A | -8 | N/A |
12/31/2014 | 5 | -10 | N/A | -5 | N/A |
9/30/2014 | 6 | -5 | N/A | -6 | N/A |
12/31/2013 | 12 | 0 | N/A | -3 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de PIRS es superior a la tasa de ahorro (2.6%).
Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de PIRS crezcan más rápidamente que el mercado US
Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de PIRS crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de PIRS crezcan más rápidamente que el mercado de US.
Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de PIRS crezcan a un ritmo superior a 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PIRS se prevé que sea elevada dentro de 3 años.